A discounted autoimmune CAR‑T “immune reset” pioneer with multiple pivotal shots on goal—if safety, scale, and funding hold, rese‑cel could redefine chronic autoimmune care.
Overview
Cabaletta Bio (CABA) is a late-stage clinical biotech focused on engineered T-cell therapies for B-cell–mediated autoimmune disease, aiming to translate the transformative impact of oncology CAR‑T into a curative “immune reset” model. Its lead asset, rese‑cel (resecabtagene autoleucel; formerly CABA‑201), is a fully human CD19-targeting CAR‑T being tested across high-unmet-need diseases including systemic lupus erythematosus, lupus nephritis, myositis, systemic sclerosis, and generalized myasthenia gravis. The central value proposition is a one-time, potentially curative intervention that transiently but profoundly depletes CD19+ B cells, allowing repopulation with a healthier B-cell repertoire and potentially eliminating lifelong immunosuppression. As a pre-revenue company, Cabaletta’s value creation hinges on clinical/regulatory milestone execution and manufacturing readiness rather than current earnings. The company has raised capital through equity markets, including a June 2025 offering generating roughly $94M net proceeds, and reported cash of ~$159.9M as of Sept. 30, 2025, with runway expected into 2H 2026. It targets large markets with meaningful morbidity and limited durable options—such as ~320,000 U.S. SLE patients (with ~40% lupus nephritis) and ~75,000 U.S. myositis patients—positioning rese‑cel as a potential entrant into the growing multi‑billion‑dollar autoimmune therapeutics landscape. The investment case is a high-upside, high-risk bet on multi‑indication pivotal progress, differentiated delivery (including potential no‑preconditioning), and scalable manufacturing to enable broader adoption in non-oncology settings.